Skip to main content
Clinical Trials/NCT07267312
NCT07267312CompletedNot Applicable

Premature Coronary Artery Disease and Familial Dyslipidemia in Patients Presenting With Acute Coronary Syndrome: A Tertiary Cardiac Center Registry

Cairo University1 site in 1 country2,000 target enrollmentStarted: December 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
2,000
Locations
1
Primary Endpoint
Dyslipidemia pattern in patients with acute coronary syndrome

Study Overview

Brief Summary

This study aimed to explore the relationship between familial hypercholesterolemia and premature coronary artery disease, particularly in the context of acute coronary syndrome, by reviewing current evidence and highlighting the need for improved screening and aggressive lipid-lowering strategies in high-risk populations.

Detailed Description

Dyslipidaemia and familial hypercholesterolemia (FH) are a common disorder that causes premature coronary artery disease.

The lifelong burden of elevated low-density lipoprotein cholesterol (LDL-C) in FH accelerates endothelial dysfunction and plaque formation, often culminating in acute coronary syndrome (ACS) at a young age. ACS in patients with undiagnosed FH may be their first clinical manifestation, underscoring the importance of early identification and intervention.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years at the time of presentation.
  • Both sexes.
  • Confirmed diagnosis of coronary artery disease (CAD), established by clinical presentation, electrocardiographic findings, elevated cardiac biomarkers, and/or angiographic evidence of ≥50% luminal stenosis in at least one major coronary artery.
  • Hospital admission to the participating cardiology department between [insert study period, e.g., January 2020 and December 2024] for acute coronary syndrome (ACS), including unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).
  • Availability of complete clinical, laboratory, and echocardiographic data necessary for classification and analysis.

Exclusion Criteria

  • Incomplete medical records or missing essential laboratory, imaging, or demographic data.
  • Secondary causes of dyslipidemia, including uncontrolled hypothyroidism, nephrotic syndrome, chronic liver disease, or use of lipid-altering medications (other than statins) before presentation.
  • Previous congenital or structural heart disease, cardiomyopathy, or significant valvular heart disease unrelated to CAD.
  • Severe chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m²) or patients on dialysis.
  • Autoimmune, inflammatory, or systemic diseases known to influence vascular inflammation or lipid metabolism.
  • Malignancy or life expectancy <6 months due to non-cardiac causes.
  • Pregnant or lactating women.
  • Non-Saudi patients (focusing on Saudi population in southern region).

Outcomes

Primary Outcomes

Dyslipidemia pattern in patients with acute coronary syndrome

Time Frame: Within 24 hours of hospital admission

Dyslipidemia pattern in patients with acute coronary syndrome was recorded.

Incidence of familial dyslipidemia among patients with acute coronary syndrome

Time Frame: Within 24 hours of hospital admission

Incidence of familial dyslipidemia among patients with acute coronary syndrome was recorded.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mohamed Hassan Senara

Cardiovascular Medicine Department, Cairo University, Cairo, Egypt.

Cairo University

Study Sites (1)

Loading locations...

Similar Trials